---
title: "Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301211.SZ.md"
symbol: "301211.SZ"
name: "Hubei Biocause Heilen Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T18:26:39.278Z"
locales:
  - [en](https://longbridge.com/en/quote/301211.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301211.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301211.SZ.md)
---

# Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)

## Company Overview

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw materials abiraterone acetate, fludarabine phosphate, and granisetron hydrochloride; and preparation products, such as cardiovascular preparations torsemide tablets and non-steroidal anti-inflammatory preparations ibuprofen granules, and other preparations.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.biocause.com](https://www.biocause.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.49)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 138 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.71% |  |
| Net Profit YoY | -47.59% |  |
| P/B Ratio | 2.03 |  |
| Dividend Ratio | 1.56% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4635238084.64 |  |
| Revenue | 459841193.81 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1.47% | D |
| Profit Margin | 7.36% | B |
| Gross Margin | 20.93% | D |
| Revenue YoY | 8.71% | B |
| Net Profit YoY | -47.59% | D |
| Total Assets YoY | -2.89% | D |
| Net Assets YoY | -1.66% | D |
| Cash Flow Margin | -2.87% | D |
| OCF YoY | 8.71% | B |
| Turnover | 0.19 | D |
| Gearing Ratio | 4.90% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hubei Biocause Heilen Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.71%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-47.59%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.03",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.56%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4635238084.64",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "459841193.81",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "1.47%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "7.36%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "20.93%",
          "rating": "D"
        },
        {
          "name": "Revenue YoY",
          "value": "8.71%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-47.59%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.89%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-1.66%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-2.87%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "8.71%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "4.90%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 134.29 | 150/215 | 144.38 | 135.93 | 118.06 |
| PB | 1.99 | 83/215 | 2.42 | 2.30 | 2.21 |
| PS (TTM) | 9.89 | 184/215 | 12.73 | 12.21 | 11.37 |
| Dividend Yield | 1.59% | 84/215 | 1.44% | 1.37% | 1.31% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/301211.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/301211.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/301211.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/301211.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**